Silk Road Medical (NASDAQ:SILK) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Silk Road Medical (NASDAQ:SILK) released its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.04, Briefing.com reports. Silk Road Medical had a negative return on equity of 35.12% and a negative net margin of 29.02%. The business had revenue of $48.50 million for the quarter, compared to the consensus estimate of $44.67 million. During the same period in the previous year, the company posted ($0.43) earnings per share. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. Silk Road Medical updated its FY 2024 guidance to EPS.

Silk Road Medical Stock Down 2.4 %

NASDAQ SILK opened at $19.67 on Thursday. The stock’s 50-day moving average price is $17.63 and its 200-day moving average price is $13.49. The company has a quick ratio of 6.97, a current ratio of 7.95 and a debt-to-equity ratio of 0.50. Silk Road Medical has a 52 week low of $6.08 and a 52 week high of $43.51. The company has a market capitalization of $775.78 million, a P/E ratio of -14.72 and a beta of 1.43.

Insider Transactions at Silk Road Medical

In related news, insider Andrew S. Davis sold 5,481 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $94,108.77. Following the completion of the sale, the insider now owns 287,773 shares in the company, valued at $4,941,062.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Silk Road Medical news, insider Andrew S. Davis sold 5,481 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $94,108.77. Following the completion of the transaction, the insider now owns 287,773 shares in the company, valued at approximately $4,941,062.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Marie L. Jones sold 2,602 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $17.17, for a total value of $44,676.34. Following the transaction, the chief accounting officer now owns 76,894 shares of the company’s stock, valued at approximately $1,320,269.98. The disclosure for this sale can be found here. Insiders have sold 20,457 shares of company stock valued at $351,247 over the last quarter. 6.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Lake Street Capital began coverage on Silk Road Medical in a report on Wednesday, January 3rd. They issued a “buy” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday. Piper Sandler increased their target price on Silk Road Medical from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. Argus raised Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Thursday, March 7th. Finally, Stifel Nicolaus increased their target price on Silk Road Medical from $20.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $22.55.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.